CSIMarket
 
Theravance Biopharma inc   (NASDAQ: TBPH)
Other Ticker:  
 
 
Price: $9.3000 $-0.21 -2.208%
Day's High: $9.56 Week Perf: -1.8 %
Day's Low: $ 9.28 30 Day Perf: 0.54 %
Volume (M): 210 52 Wk High: $ 10.90
Volume (M$): $ 1,949 52 Wk Avg: $8.94
Open: $9.51 52 Wk Low: $7.44



 Market Capitalization (Millions $) 456
 Shares Outstanding (Millions) 49
 Employees 180
 Revenues (TTM) (Millions $) 61
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) -50
 Capital Exp. (TTM) (Millions $) 0

Theravance Biopharma Inc
Theravance Biopharma Inc. is a pharmaceutical company that specializes in the discovery, development, and commercialization of small molecule medicines. They focus on various therapeutic areas including respiratory diseases, gastrointestinal disorders, and infectious diseases. Their objective is to create innovative treatments that improve patient care and offer significant advancements in the field of biopharmaceutical research. The company utilizes a proprietary technology platform to identify new drug candidates and aims to deliver breakthrough therapies that address unmet medical needs.


   Company Address: C/O Theravance Biopharma US, Inc. South San Francisco 94080 CA
   Company Phone Number: 808-6000   Stock Exchange / Ticker: NASDAQ TBPH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.17%    
JNJ        0.82% 
LLY        8.38% 
MRK   -12.54%    
PFE   -1.76%    
VTRS   -2.81%    
• View Complete Report
   



Theravance Biopharma Inc

Theravance Biopharma Inc Reports Exceptional 24.425% Revenue Gain in Second Quarter of 2023, Outperforming Industry Peers


Introduction
Theravance Biopharma Inc, a major player in the pharmaceutical preparations industry, recently unveiled its financial report for the second quarter of 2023. While the company reported a significant increase in revenue by 24.425% to $13.75 million compared to the same period the previous year, it also experienced widening diminishing returns, resulting in a loss of $-0.28 per share. In a broader industry context, Theravance Biopharma's top-line improvements outpaced its peers, which observed an average revenue growth of 2.65%. This article will examine the financial results of Theravance Biopharma Inc, placing them within the larger industry context.
Revenue Growth and EPS Improvement
Theravance Biopharma Inc witnessed an impressive surge in revenue during Q2 2023, with an increase of 24.425% to $13.75 million compared to the same reporting period a year ago. In terms of earnings per share (EPS), the company also displayed improvement, moving from $-0.35 per share to $-0.28 per share. This positive momentum suggests that Theravance Biopharma Inc is effectively navigating the market by increasing its revenue and reducing its losses on a per-share basis.

Theravance Biopharma Inc

Theravance Biopharma Inc Shatters Expectations with +153.08% ROA in First Quarter

Theravance Biopharma Inc reports impressive first quarter results
Theravance Biopharma Inc, a leading healthcare company, has recently announced its financial results for the first quarter of 2023, exceeding expectations with a return on asset (ROA) of 153.08%. This is a significant improvement from the company's average ROA of -30.48%, demonstrating the company's strong performance in the pharmaceutical industry.
Despite a decrease in net income, Theravance Biopharma Inc reported impressive results in the healthcare sector, posting the highest return on assets. The company's overall ranking has also advanced, moving up to the 3rd position from the 14th position in the fourth quarter of 2022.







Theravance Biopharma Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com